Delivery of chemotropic proteins and improvement of dopaminergic neuron outgrowth through a thixotropic hybrid nano-gel

Journal of Materials Science: Materials in Medicine

Volumn 22, Issue 9, 2011, Pages 2097-2109

  Tamariz, Elisa ^a   Wan, Andrew C A ^b   Pek, Y Shona ^b   Giordano, Magda ^c   Hernández Padrón, Genoveva ^d   Varela Echavarría, Alfredo ^c   Velasco, Iván ^e   Castaño, Víctor M ^d  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

^d CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^e INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC; DOPAMINERGIC NEURONS; EMBRYO DEVELOPMENT; FUNCTIONAL GRADIENT; GLIAL CELLS; INFLAMMATORY RESPONSE; RAT EMBRYO; SHORT TERM; SILICA PARTICLES; SITE-SPECIFIC; STRIATUM; THIXOTROPIC PROPERTIES; TRANSPLANTATION THERAPY;

BIODEGRADATION; CELL CULTURE; DEGRADATION; ETHYLENE; GELS; GLYCOLS; NANOCOMPOSITES; NEURONS; POLYETHYLENE GLYCOLS; SILICA; STEM CELLS;

PROTEINS;

MACROGOL; NANOCOMPOSITE; NANOCOMPOSITE GEL; SEMAPHORIN 3A; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; EMBRYO; GLIA CELL; IMPLANTATION; INFLAMMATION; MACROPHAGE; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL;

ANIMALS; BIOCOMPATIBLE MATERIALS; DOPAMINE; GANGLIA, SPINAL; NANOSTRUCTURES; NEURONS; POLYETHYLENE GLYCOLS; RATS; RECOMBINANT PROTEINS; SEMAPHORIN-3A; SPECTRUM ANALYSIS, RAMAN;

RATTUS;

EID: 80755139638     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-011-4385-5     Document Type: Article

References (74)

1. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature. 2003;423:573-4. (Pubitemid 36713190)
2. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2006;79:141-52.
3. Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am. 2010;24:497-514.
4. McRae A, Hjorth S, Mason DW, Dillon L, Tice TR. Microencapsulated dopamine (DA)-induced restitution of function in 6-OHDA-denervated rat striatum in vivo: comparison between two microsphere excipients. J Neural Transplant Plast. 1991;2: 165-73.
5. Maysinger D, Jalsenjak I, Cuello AC. Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions. Neurosci Lett. 1992;140:71-4.
6. Klose D, Siepmann F, Willart JF, Descamps M, Siepmann J. Drug release from PLGA-based microparticles: effects of the "microparticle:bulk fluid" ratio. Int J Pharm. 2009;383:123-31.
7. Nkansah MK, Tzeng SY, Holdt AM, Lavik EB. Poly(lactic-coglycolic acid) nanospheres and microspheres for short- and longterm delivery of bioactive ciliary neurotrophic factor. Biotechnol Bioeng. 2008;100:1010-9.
8. Burdick JA, Ward M, Liang E, Young MJ, Langer R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials. 2006;27:452-9. (Pubitemid 41457248)
9. Jain A, Kim YT, McKeon RJ, Bellamkonda RV. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials. 2006;27: 497-504. (Pubitemid 41457252)
10. Piantino J, Burdick JA, Goldberg D, Langer R, Benowitz LI. An injectable, biodegradable hydrogel for trophic factor delivery enhances axonal rewiring and improves performance after spinal cord injury. Exp Neurol. 2006;201:359-67. (Pubitemid 44344229)
11. Jhaveri SJ, Hynd MR, Dowell-Mesfin N, Turner JN, Shain W, Ober CK. Release of nerve growth factor from HEMA hydrogelcoated substrates and its effect on the differentiation of neural cells. Biomacromolecules. 2009;10:174-83.
12. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface. 2011;8:153-70.
13. Bagnard D, Lohrum M, Uziel D, Puschel AW, Bolz J. Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development. 1998;125: 5043-53. (Pubitemid 29026785)
14. Bagnard D, Thomasset N, Lohrum M, Puschel AW, Bolz J. Spatial distributions of guidance molecules regulate chemorepulsion and chemoattraction of growth cones. J Neurosci. 2000;20:1030-5. (Pubitemid 30220460)
15. Rosentreter SM, Davenport RW, Loschinger J, Huf J, Jung J, Bonhoeffer F. Response of retinal ganglion cell axons to striped linear gradients of repellent guidance molecules. J Neurobiol. 1998;37:541-62. (Pubitemid 28549216)
16. Isbister CM, Mackenzie PJ, To KC, O'Connor TP. Gradient steepness influences the pathfinding decisions of neuronal growth cones in vivo. J Neurosci. 2003;23:193-202. (Pubitemid 36050419)
17. Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee. Cell. 1999;97:551-52.
18. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274:1123-33. (Pubitemid 26389268)
19. Messersmith EK, Leonardo ED, Shatz CJ, Tessier-Lavigne M, Goodman CS, Kolodkin AL. Semaphorin III can function as a selective chemorepellent to pattern sensory projections in the spinal cord. Neuron. 1995;14:949-59.
20. Moreno-Flores MT, Martin-Aparicio E, Martin-Bermejo MJ, Agudo M, McMahon S, Avila J, Diaz-Nido J, Wandosell F. Semaphorin 3C preserves survival and induces neuritogenesis of cerebellar granule neurons in culture. J Neurochem. 2003;87: 879-90. (Pubitemid 37444564)
21. Polleux F, Morrow T, Ghosh A. Semaphorin 3A is a chemoattractant for cortical apical dendrites. Nature. 2000;404:567-73. (Pubitemid 30205047)
22. Hernandez-Montiel HL, Tamariz E, Sandoval-Minero MT, Varela- Echavarria A. Semaphorins 3A, 3C, and 3F in mesencephalic dopaminergic axon pathfinding. J Comp Neurol. 2008;506: 387-97.
23. Mann F, Chauvet S, Rougon G. Semaphorins in development and adult brain: implication for neurological diseases. Prog Neurobiol. 2007;82:57-79. (Pubitemid 46829602)
24. Song H, Ming G, He Z, Lehmann M, McKerracher L, Tessier- Lavigne M, Poo M. Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science. 1998;281:1515-8. (Pubitemid 28425577)
25. Terman JR, Kolodkin AL. Nervy links protein kinase a to plexinmediated semaphorin repulsion. Science. 2004;303:1204-7. (Pubitemid 38233588)
26. Castellani V, De Angelis E, Kenwrick S, Rougon G. Cis and trans interactions of L1 with neuropilin-1 control axonal responses to semaphorin 3A. EMBO J. 2002;21:6348-57. (Pubitemid 35448413)
27. Falk J, Bechara A, Fiore R, Nawabi H, Zhou H, Hoyo-Becerra C, Bozon M, Rougon G, Grumet M, Puschel AW, Sanes JR, Castellani V. Dual functional activity of semaphorin 3B is required for positioning the anterior commissure. Neuron. 2005;48:63-75. (Pubitemid 41384166)
28. Schlomann U, Schwamborn JC, Muller M, Fassler R, Puschel AW. The stimulation of dendrite growth by Sema3A requires integrin engagement and focal adhesion kinase. J Cell Sci. 2009;122:2034-42.
29. Tamariz E, Diaz-Martinez NE, Diaz NF, Garcia-Pena CM, Velasco I, Varela-Echavarria A. Axon responses of embryonic stem cell-derived dopaminergic neurons to semaphorins 3A and 3C. J Neurosci Res. 2010;88:971-80.
30. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50-6. (Pubitemid 34742566)
31. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18:675-9. (Pubitemid 30415305)
32. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136:964-77.
33. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA. 2008;105: 5856-61. (Pubitemid 351758462)
34. Bjorklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol Scand Suppl. 1983;522:9-18. (Pubitemid 14153752)
35. Isacson O, Bjorklund LM, Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol. 2003;53(Suppl 3):S135-46.
36. Pek YS, Wan AC, Shekaran A, Zhuo L, Ying JY. A thixotropic nanocomposite gel for three-dimensional cell culture. Nat Nanotechnol. 2008;3:671-5.
37. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997; 90:753-62. (Pubitemid 27357966)
38. Diaz NF, Guerra-Arraiza C, Diaz-Martinez NE, Salazar P, Molina- Hernandez A, Camacho-Arroyo I, Velasco I. Changes in the content of estrogen alpha and progesterone receptors during differentiation of mouse embryonic stem cells to dopamine neurons. Brain Res Bull. 2007;73:75-80. (Pubitemid 46710248)
39. Kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. J Biomed Mater Res. 1990;24:721-34. (Pubitemid 20236523)
40. Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell. 1993;75:217-27. (Pubitemid 23320286)
41. Dupeyron D, Rieumont J, González M, Castaño VM. Protein delivery by enteric copolymer nanoparticles. J Dispers Sci Technol. 2009;30:1-7.
42. Colthup BN, Daly HL, Wiberley ES. Introduction to infrared and Raman spectroscopy. 3rd ed. San Diego: Academic Press; 1990.
43. Nakamoto K. Infrared and Raman spectra of inorganic and coordination compounds. 3rd ed. New York: Wiley; 1978.
44. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA. 2010;107:15921-6.
45. Mendez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci. 1996;16:7216-27. (Pubitemid 26382898)
46. Thompson LH, Grealish S, Kirik D, Bjorklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci. 2009;30:625-38.
47. Gaillard A, Decressac M, Frappe I, Fernagut PO, Prestoz L, Besnard S, Jaber M. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol Dis. 2009;35:477-88.
48. Baker KA, Sadi D, Hong M, Mendez I. Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft. J Comp Neurol. 2000;426:106-16.
49. Nikkhah G, Cunningham MG, Cenci MA, McKay RD, Bjorklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci. 1995;15:3548-61.
50. Nikkhah G, Cunningham MG, McKay R, Bjorklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. II. Transplant-induced behavioral recovery. J Neurosci. 1995;15:3562-70.
51. Lee JK, Geoffroy CG, Chan AF, Tolentino KE, Crawford MJ, Leal MA, Kang B, Zheng B. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron. 2010;66:663-70.
52. Omoto S, Ueno M, Mochio S, Takai T, Yamashita T. Genetic deletion of paired immunoglobulin-like receptor B does not promote axonal plasticity or functional recovery after traumatic brain injury. J Neurosci. 2010;30:13045-52.
53. Nakamura Y, Fujita Y, Ueno M, Takai T, Yamashita T. Paired immunoglobulin-like receptor B knockout does not enhance axonal regeneration or locomotor recovery after spinal cord injury. J Biol Chem. 2011;286:1876-83.
54. Van den Heuvel DM, Pasterkamp RJ. Getting connected in the dopamine system. Prog Neurobiol. 2008;85:75-93.
55. Krieglstein K. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res. 2004;318:73-80. (Pubitemid 39362628)
56. Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, Hoffer B, Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol. 1993;124:401-12. (Pubitemid 24041791)
57. Tang FI, Tien LT, Zhou FC, Hoffer BJ, Wang Y. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats. Exp Brain Res. 1998;119:287-96. (Pubitemid 28118736)
58. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6: 1794-805.
59. He X, Nie H, Wang K, Tan W, Wu X, Zhang P. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem. 2008;80:9597-603.
60. Burns AA, Vider J, Ow H, Herz E, Penate-Medina O, Baumgart M, Larson SM, Wiesner U, Bradbury M. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett. 2009;9:442-8.
61. Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials. 2008;29:4045-55.
62. Calandrelli L, Annunziata M, Della Ragione F, Laurienzo P, Malinconico M, Oliva A. Development and performance analysis of PCL/silica nanocomposites for bone regeneration. J Mater Sci Mater Med. 2010;21:2923-36.
63. D'Agostino A, Errico ME, Malinconico M, De Rosa M, Avella M, Schiraldi C. Development of nanocomposite based on hydroxyethylmethacrylate and functionalized fumed silica: mechanical, chemico-physical and biological characterization. J Mater Sci Mater Med. 2011;22:481-90.
64. Witasp E, Kupferschmidt N, Bengtsson L, Hultenby K, Smedman C, Paulie S, Garcia-Bennett AE, Fadeel B. Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. Toxicol Appl Pharmacol. 2009;239:306-19.
65. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta. 2010;1810:361-73.
66. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847-56.
67. Vallhov H, Gabrielsson S, Stromme M, Scheynius A, Garcia- Bennett AE. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 2007;7:3576-82.
68. Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials. 2010;31:438-48.
69. Dutta D, Sundaram SK, Teeguarden JG, Riley BJ, Fifield LS, Jacobs JM, Addleman SR, Kaysen GA, Moudgil BM, Weber TJ. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci. 2007;100:303-15. (Pubitemid 47617826)
70. Cauda V, Schlossbauer A, Bein T. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microp Mesop Mater. 2010;132:60-71.
71. Xu H, Yan F, Monson EE, Kopelman R. Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications. J Biomed Mater Res. 2003;A 66:870-9. (Pubitemid 37521413)
72. Nikkhah G, Olsson M, Eberhard J, Bentlage C, Cunningham MG, Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience. 1994;63:57-72. (Pubitemid 24333952)
73. Olanow CW. Surgical therapy for Parkinson's disease. Eur J Neurol. 2002;9(Suppl 3):31-9. (Pubitemid 35471981)
74. Steiner B, Winter C, Blumensath S, Paul G, Harnack D, Nikkhah G, Kupsch A. Survival and functional recovery of transplanted human dopaminergic neurons into hemiparkinsonian rats depend on the cannula size of the implantation instrument. J Neurosci Methods. 2008;169:128-34.